Ritholtz Wealth Management’s Spyre Therapeutics SYRE Stock Holding History

Ritholtz Wealth Management’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,671	Closed	-$12.1K	–	705
2023 Q1	$12.1K	Sell	1,671 -1,389	-45%	-$15.2K	﹤0.01%	637
2022 Q4	$34.4K	Hold	3,060	–	–	﹤0.01%	571
2022 Q3	$40K	Hold	3,060	–	–	﹤0.01%	707
2022 Q2	$39K	Hold	3,060	–	–	﹤0.01%	538
2022 Q1	$176K	Hold	3,060	–	–	0.01%	520
2021 Q4	$363K	Hold	3,060	–	–	0.02%	372
2021 Q3	$608K	Sell	3,060 -3,926	-56%	-$687K	0.04%	227
2021 Q2	$1.22M	Hold	6,986	–	–	0.09%	113
2021 Q1	$1.38M	Hold	6,986	–	–	0.12%	84
2020 Q4	$1.37M	Hold	6,986	–	–	0.13%	69
2020 Q3	$1.24M	Hold	6,986	–	–	0.14%	68
2020 Q2	$1.61M	Sell	6,986 -2,000	-22%	-$381K	0.21%	45
2020 Q1	$1.05M	Sell	8,986 -800	-8%	-$136K	0.17%	49
2019 Q4	$1.87M	Sell	9,786 -800	-8%	-$157K	0.27%	35
2019 Q3	$2.04M	Sell	10,586 -1,035	-9%	-$202K	0.33%	30
2019 Q2	$1.99M	Hold	11,621	–	–	0.34%	30
2019 Q1	$2.34M	Hold	11,621	–	–	0.43%	26
2018 Q4	$2.18M	Buy	+11,621	New	+$2.47M	0.49%	28

Other funds holding SYRE

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ritholtz Wealth Management's SYRE Position: Q2 2023 in Review

Ritholtz Wealth Management sold out of Spyre Therapeutics (SYRE) in Q2 2023, closing a stake of 1,671 shares — an estimated $12.1K sold.

Ritholtz Wealth Management first reported a position in SYRE in Q4 2018 and held it in 18 quarters. The position peaked at $2.34M in Q1 2019. 43 funds tracked by Wall St. Rank hold SYRE as of Q2 2023.

Ritholtz Wealth Management reported no remaining Spyre Therapeutics position as of Q2 2023 after selling out during the quarter.
Ritholtz Wealth Management sold 1,671 Spyre Therapeutics shares in Q2 2023, an estimated $12.1K.
Ritholtz Wealth Management first reported a position in Spyre Therapeutics in Q4 2018 and held it in 18 quarters.
Ritholtz Wealth Management's Spyre Therapeutics position peaked at $2.34M in Q1 2019.
43 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2023.

Based on Ritholtz Wealth Management's 13F filing for Q2 2023, filed 17 Jul 2023.